Comparison of effect of crystalloids versus albumin for goal directed fluid therapy on peri-operative outcomes in major abdomino-pelvic oncological surgeries: a randomized control trial

Comparison of effect of crystalloids versus albumin for goal directed fluid therapy on peri-operative outcomes in major abdomino-pelvic oncological surgeries: a randomized control trial - nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063106

Enrollment

170

Registered

2024-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: 5% Albumin (colloid): Patients will be randomly allocated to RL or AL group. Post induction of anaesthesia, the patients in both the groups will receive lactated ringersâ?? at 4ml/kg/ho

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged >18 years, with American Society of Anesthesiology Physical Status (ASA PS) 1-3, scheduled to undergo elective major abdomino-pelvic oncological surgeries that are expected to last >2 hours. patient undergoing surgery with expected blood loss > 300ml

Exclusion criteria

Exclusion criteria: age Patients with decompensated ischemic heart disease, left ventricular ejection fraction , preoperative creatinine > 2 mg/dl, renal failure, oliguria or anuria or on hemodialysis, coagulopathy, impaired liver function, Pregnant and lactating patients.

Design outcomes

Primary

Measure	Time frame
Post-operative morbidity survey score (POMS) on post-operative day 2Timepoint: Post-operative day 2	—

Secondary

Measure	Time frame
Intraoperatively: HR, MAP, PPV, SVV, CI, total fluid administered, total number of fluid boluses, urine output, estimated blood loss, blood products transfused, total vasopressor requirement, inotrope requirement.Post-operatively: ABG, changes in coagulation profile & kidney function on POD â?? 0, 1, Length of stay in ICU/hospital, requirement of additional inotropic support, blood transfusion, incidence of complications during hospital admission.Timepoint: Intraoperatively: HR, MAP, PPV, SVV, CI measured every 15 minutes. Total fluid, urine output, blood loss measured hourly. Number of fluid boluses, blood products, vasopressor/inotrope requirement will be added at the end of the case. Post-operatively:ABG, coagulation profile & kidney function on POD-0&1.Length of stay in ICU/hospital, inotropic support, blood transfusion, post-operative complications will be noted throughout hospital stay.	—

Measure

Time frame

Intraoperatively: HR, MAP, PPV, SVV, CI, total fluid administered, total number of fluid boluses, urine output, estimated blood loss, blood products transfused, total vasopressor requirement, inotrope requirement.Post-operatively: ABG, changes in coagulation profile & kidney function on POD â?? 0, 1, Length of stay in ICU/hospital, requirement of additional inotropic support, blood transfusion, incidence of complications during hospital admission.Timepoint: Intraoperatively: HR, MAP, PPV, SVV, CI measured every 15 minutes. Total fluid, urine output, blood loss measured hourly. Number of fluid boluses, blood products, vasopressor/inotrope requirement will be added at the end of the case. Post-operatively:ABG, coagulation profile & kidney function on POD-0&1.Length of stay in ICU/hospital, inotropic support, blood transfusion, post-operative complications will be noted throughout hospital stay.

—

Countries

India

Contacts

Public ContactDr Vasudha Ahuja

National Cancer Institue-AIIMS, Jhajjar

anujapandit@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 9, 2026